Skip to content

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
15%+3.8pp
Pfizer logo
PfizerPFE
15.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
21.8%-2.6pp
Merck & Co. logo
Merck & Co.MRK
13.6%-13.7pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-606.2%-212pp
CG Oncology logo
CG OncologyCGON
-3,682.6%-1,601pp

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

Based on trailing twelve months.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's net margin?
UroGen Pharma (URGN) reported net margin of -94.8% in Q1 2026.
How has UroGen Pharma's net margin changed year-over-year?
UroGen Pharma's net margin increased by 37.1% year-over-year, from -150.7% to -94.8%.
What is the long-term trend for UroGen Pharma's net margin?
Over 5 years (2020 to 2025), UroGen Pharma's net margin has grown at a -33.7% compound annual growth rate (CAGR), from -1,088.9% to -139.8%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.